Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

• Customized drug discovery offers integrated target-to-lead and target-to-clinic ready small molecules

Excerpt from the Press Release:

WILMINGTON, Mass. & BOSTON–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Logica^TM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination.

“Through our partnership with Valo, we’re integrating Charles River’s laboratory capabilities with industry-altering AI-driven molecular design to provide our clients with highly advanceable leads and candidates, while tying client costs to value generation,” said Birgit Girshick, Corporate Executive Vice President & Chief Operating Officer, Charles River. “AI-powered solutions are driving drug discovery forward and this is the kind of innovation our industry needs to ultimately bring effective treatments to patients faster.”

“Valo is thrilled to partner with Charles River on this first of its kind offering,” added David Berry, MD, Ph.D., founder, and CEO of Valo. “We are creating an opportunity to fully outsource small molecule discovery while providing a true risk-sharing model with advanceable leads and candidates with the goal of helping companies scale faster, translating more biological insight into candidates to make better drugs for patients, faster.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release